在Aβ治疗的神经元和APP/PS1小鼠中,IDO1抑制的保护作用
Zhenzhen Duan1, Lei Shi1, Zhen Ning Tony He1
1School of Life Sciences, Shanghai Engineering Research Center of Industrial Microorganisms, Fudan University, Shanghai, China.
American journal of Alzheimer's disease and other dementias
|November 9, 2023
概括
阿尔茨海默病涉及炎症和失调的 kynurenine 途径 (KP). 向胺2,3-二氧化酶1 (IDO1) 酶对治疗阿尔茨海默病中神经炎症的治疗有希望.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 与炎症和失调的金氨酸通路 (KP) 有关.
- 酶胺2,3-二氧化酶1 (IDO1) 启动了KP,产生神经活性代谢产物.
- 在AD中观察到IDO1过度激活和KP代谢物积累,这表明IDO1是治疗点.
研究的目的:
- 在AD中调查KP酶表达和IDO1活性.
- 探索KP酶和AD病原体之间的关系.
- 在AD模型中评估IDO1抑制剂的治疗潜力.
主要方法:
- 在AD小鼠中检查了炎症性细胞因子,神经营养因子和KP酶.
- 评估了IDO1活性和基碳化合物受体 (AhR) 途径.
- 在初级神经元,海马细胞和APP/PS1小鼠中测试了IDO1抑制剂.
主要成果:
- 证实了IDO1催化KP在AD神经炎症中的重要性.
- 证明了IDO1抑制剂对Aβ相关的神经炎症的影响.
- 提供了关于AD中KP酶表达模式的见解.
结论:
- 在阿尔茨海默氏症神经炎症中,IDO1-催化基努伦因通路至关重要.
- 向IDO1为阿尔茨海默病提供了潜在的治疗策略.
- 对于AD治疗,对KP调节的进一步研究是有必要的.
相关概念视频
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...